adalimumab + ustekinumab

The combination of adalimumab and ustekinumab represents a dual biologic therapy approach used primarily for treating inflammatory conditions. ## Mechanism of Action Adalimumab is a tumor necrosis factor (TNF) blocker that works by inhibiting TNF-alpha, a key inflammatory cytokine involved in immune and inflammatory responses. Ustekinumab, on the other hand, is a human immunoglobulin G1 kappa monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), which are cytokines involved in inflammatory pathways. The combination therapy leverages these complementary mechanisms to potentially provide enhanced efficacy in treating inflammatory conditions that have been resistant to monotherapy approaches. ## Clinical Use The adalimumab + ustekinumab combination has been studied primarily in inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. This combination represents part of a broader approach known as dual biologic therapy (DBT), where two biologic agents are used simultaneously to manage refractory cases of inflammatory conditions. ## Safety Considerations Safety concerns have been raised regarding combination biologic therapies. Studies have shown that patients receiving combination therapy may have a higher rate of serious adverse events compared to monotherapy. The risk of adverse effects can be increased when adalimumab is combined with ustekinumab. ## Clinical Evidence Limited clinical data exists on this specific combination. In one retrospective cohort study, adalimumab plus ustekinumab was the most frequently used dual biologic therapy combination in a cohort of patients, with a median follow-up of nine months, and 32% of patients achieving remission.

Other names

adalimumab and ustekinumab combination